Microfluidic Point-of-care Cancer Cell Analyzer

微流控床旁癌细胞分析仪

• 批准号: 6733841
• 负责人: Charles FRED BATTRELL
• 金额: $ 10万
• 依托单位: MICRONICS, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-03-08 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6733841
• 关键词: CD34 molecule; antigens; biomedical equipment development; blood tests; charge coupled device camera; chronic myelogenous leukemia; clinical research; computer program /software; flow cytometry; fluid flow; gene expression; genetic markers; human tissue; messenger RNA; neoplastic cell; nucleic acid amplification techniques; nucleic acid sequence

DESCRIPTION (provided by applicant): Micronics, Inc., and Xtrana, lnc., will develop an inexpensive point of care cancer marker detection device. The device will integrate and automate blood sample preparation, cell sorting and enrichment by microcytometry, antigen (CD marker) analysis, and both DNA sequence and gene expression analysis. Micronics has developed a technology platform for performing microfluidic processes on laminate-based disposables. The technology comprises microfluidic cartridges assembled from plastic laminates, a computer-controlled fluid driver system, pneumatic and passive on-chip valving capability using accurate Iow-pulsatility pumps, and computer software to control fluid motion in the cartridge. Xtrana has developed a novel series of products and applications centered around unique capabilities in nucleic acid sample preparation. Key to the sample preparation is a family of materials, referred to as Xtra Bind, that bind nucleic acids essentially irreversibly, but still allow the bound DNA or RNA to be amplified using conventional methods like PCR. The project will require research and proof-of-principle experiments in the area of microfluidic cell marker identification and sorting, as well as in on-chip cell lysing and microfluidics-based nucleic acid amplification and detection. Specifically, experiments involving fluorescence detection on micro-cytometer card, accurate counting and display of fluorescent beads of different sizes as well as beads conjugated with antigen, tagged by antibody and counted on micro-cytometer will be performed initially, followed by sorting/fluorescence gating on micro-cytometer. At the same time, Xtrana will develop the protocols for the Xtra BindTM BCR/ABL mRNA expression measurement and will experimentally determine limit of detection and linear range of detection of bcr/abl mRNA transcripts for control cell lines spiked into white blood cells or blood. In Phase II, an instrument capable of BCR/ABL gene translocation diagnostic of chronic myeloid leukemia (CML) and the associated chimeric mRNA expression will be developed.

描述(由申请人提供)： Micronics，Inc.和Xtra，Inc.将开发一种廉价的护理点癌症标记检测设备。该设备将集成和自动化血样准备、细胞分选和微细胞术浓缩、抗原(CD标记)分析以及DNA序列和基因表达分析。Microronics已经开发了一种技术平台，用于对基于层压板的一次性产品进行微流控工艺。这项技术包括由塑料层压板组装的微流控墨盒、计算机控制的流体驱动系统、使用精确的低脉动度泵的气动和被动芯片上阀门能力，以及控制墨盒中流体运动的计算机软件。Xtrana围绕核酸样品制备的独特能力开发了一系列新颖的产品和应用。样品制备的关键是一系列被称为Xtra Bind的材料，它们基本上不可逆转地与核酸结合，但仍然允许使用常规方法，如PCR，扩增结合的DNA或RNA。 该项目将需要在微流控细胞标记识别和分选领域以及在芯片细胞裂解和基于微流控技术的核酸扩增和检测领域进行研究和原理验证实验。具体来说，首先将在微型细胞仪上进行荧光检测，对不同大小的荧光珠以及与抗原结合、抗体标记和在微型细胞仪上计数的荧光珠进行准确计数和显示，然后在微型细胞仪上进行分选/荧光选通。 与此同时，Xtra将开发Xtra BindTM BCR/ABL mRNA表达测量的方案，并将在实验中确定加入白血球或血液的对照细胞系的BCR/ABL mRNA转录本的检测极限和线性检测范围。在第二阶段，将开发一种能够诊断慢性粒细胞白血病(CML)bcr/abl基因易位和相关嵌合mRNA表达的仪器。